



Data received as of  
2020-Oct-12

European Region

Next overall update Winter 2020  
Next WHO UNICEF estimates July 2021

Population data in thousands <sup>1</sup>

	2019	2018	2017	2016	2015	2000	1990	1980
Total population	930'167	926'911	923'248	919'366	915'412	866'251	845'992	796'994
Live births	11'021	11'139	11'243	11'327	11'388	10'245	12'549	13'363
Surviving infants	10'943	11'058	11'157	11'236	11'293	10'061	12'203	12'871
Pop. less than 5 years	56'445	56'743	56'918	57'050	57'161	51'135	64'186	63'850
Pop. less than 15 years	168'691	167'678	166'347	164'902	163'485	172'232	192'087	192'390
Female 15-49 years	210'995	211'922	212'878	213'932	215'113	221'432	208'475	197'337

Number of reported cases

Diphtheria	52	73	35	48	59	1'585	3'202	618
Japanese encephalitis	0	0	3	0	1	-	-	-
Measles	106'130	89'148	24'356	4'440	25'957	37'421	234'827	851'849
Mumps	24'363	20'114	26'965	21'364	10'072	243'344	-	-
Pertussis	56'043	57'219	63'129	69'937	50'591	53'675	129'735	90'546
Polio	0	0	0	0	2	0	370	549
Rubella	671	800	842	1'472	655	621'039	-	-
Rubella (CRS)	8	14	17	6	14	47	-	-
Tetanus (neonatal)	22	0	0	0	1	27	69	26
Tetanus (total)	69	81	134	137	123	412	879	1'715
Yellow fever	0	4	0	1	0	0	-	-

Percentage of target population vaccinated, by antigen

based on WHO-UNICEF estimates  
TT2plus is based on reported coverage

BCG	92	93	92	92	90	93	84	20
DTP1	97	97	96	95	96	97	89	70
DTP3	95	95	94	92	93	93	80	63
HepB_BD	41	40	39	40	41	13	-	-
HepB3	92	84	84	82	82	42	0	-
Hib3	79	78	76	76	76	38	0	-
IPV1	95	88	71	73	69	-	-	-
MCV1	96	95	95	93	94	91	83	55
MCV2	92	91	90	88	89	48	-	-
PCV3	80	78	73	62	48	-	-	-
Pol3	95	94	93	94	94	94	84	72
RCV1	96	95	95	93	94	60	29	4
rotac	25	25	25	24	23	-	-	-
TT2plus	83	83	83	83	83	38	17	0

Most countries have standard recommendations regarding which vaccines should be offered and at what ages they should be given. In general, vaccines are recommend for the youngest age group at risk for developing the disease whose members are known to respond to the immunization without adverse effects.

Estimates for a dose of inactivated polio vaccine (IPV) begin in 2015 following the Global Polio Eradication Initiative's Polio Eradication and Endgame Strategic Plan: 2013-2018 which recommended at least one full dose or two fractional doses of IPV into routine immunization schedules as a strategy to mitigate the potential consequences should any re-emergence of type 2 poliovirus occur following the planned withdrawal of Sabin type 2 strains from oral polio vaccine (OPV). IPV global and regional coverage calculation is for 144 bOPV using countries.

Unless otherwise specified, data provided by Member States through WHO-UNICEF Joint Reporting Form and WHO Regional offices.

1) "United Nations, Population Division. The World Population Prospects - the 2019 revision". New York, 2019.